Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth O Hexner

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood Advances|April 19, 2024
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHDZachariah DeFilipp, Haesook T Kim, Nikolaos Spyrou, et al.
Blood Advances|March 29, 2022
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemiaSaar Gill, Vanessa Vides, Noelle V Frey, et al.
Transplantation and Cellular Therapy|September 2, 2021
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host DiseaseMakda Getachew Zewde, George Morales, Isha Gandhi, et al.
Blood Advances|February 11, 2026
CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemiaJason Xu, Michael McCoy, Zachary Martinez, et al.
Transplantation and Cellular Therapy|January 19, 2024
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation RecipientsAnthony D Sung, Thuy Koll, Shannon H Gier, et al.
Blood Immunology & Cellular Therapy|May 15, 2026
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRMYu Akahoshi, Nikolaos Katsivelos, Ioannis E Louloudis, et al.
Blood Advances|July 1, 2025
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGICYu Akahoshi, Yoshihiro Inamoto, Nikolaos Spyrou, et al.
Journal for Immunotherapy of Cancer|April 17, 2025
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapyRegina M Myers, Amanda M DiNofia, Yimei Li, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood Advances|April 19, 2024
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHDZachariah DeFilipp, Haesook T Kim, Nikolaos Spyrou, et al.
Blood Advances|March 29, 2022
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemiaSaar Gill, Vanessa Vides, Noelle V Frey, et al.
Transplantation and Cellular Therapy|September 2, 2021
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host DiseaseMakda Getachew Zewde, George Morales, Isha Gandhi, et al.
Blood Advances|February 11, 2026
CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemiaJason Xu, Michael McCoy, Zachary Martinez, et al.
Transplantation and Cellular Therapy|January 19, 2024
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation RecipientsAnthony D Sung, Thuy Koll, Shannon H Gier, et al.
Blood Immunology & Cellular Therapy|May 15, 2026
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRMYu Akahoshi, Nikolaos Katsivelos, Ioannis E Louloudis, et al.
Blood Advances|July 1, 2025
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGICYu Akahoshi, Yoshihiro Inamoto, Nikolaos Spyrou, et al.
Journal for Immunotherapy of Cancer|April 17, 2025
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapyRegina M Myers, Amanda M DiNofia, Yimei Li, et al.
Pageof 11